UNSPSC 51323001: Carnitine

This classification denotes a nutritional supplement, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0G389FZZ9M. European Medicines Agency schedules Carnitine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06134MIG. Carnitine generally arises in the molecular formula C7H15NO3.

The term CARNITINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, no10, 1977, list 17.) CARNITINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule carnitine under HS 29239000 and SITC 51481. As of Q4 2014, CARNITINE remains the US FDA Preferred Term for this commodity. Carnitine bears US NLM identifiers UMLS ID C0007258 and NCI Concept Code C82599. SMILES: OC(C[N](C)(C)C)CC(=O)O.

UNSPSC 51323001 Carnitine is a Commodity-tier code covering pharmaceutical ingredients and finished medications supplied to state and local health, emergency response, and public health agencies. State and local governments use this code to procure emergency medical drugs, pharmacy benefit products, and over-the-counter pharmaceuticals for fire rescue operations, state health agencies, and cooperative purchasing alliances spanning multiple jurisdictions. The issuing bodies soliciting under the code include municipal fire departments (Tampa Fire Rescue through the City of Tampa's Purchasing Department), state health agencies (Texas Health and Human Services Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). Requirements typically include cGMP certification, FDA compliance, Safety Data Sheets meeting OSHA Hazard Communication Standards, Drug Supply Chain Security Act (DSCSA) compliance, expiration dates of nine months to one year from delivery, and delivery within ten calendar days of order receipt when specified.

Geographic activity centers on Florida, Texas, and Minnesota based on recent solicitations. The City of Tampa issued an IFB (Bid No. 26P00188) on April 24, 2026 for Advanced Life Support Medications—including Labetalol, Epinephrine, Adenosine, and Diltiazem injections—with a due date of April 8, 2026 and an estimated contract value of $40,000.00 under a Small Local Business Enterprise sheltered market designation offering a 5 percent bid discount. The Texas Health and Human Services Commission issued a Request for Information (RFI HHS0017013) in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, targeting negotiated net pricing models outside traditional pharmacy benefit manager and group purchasing organization channels. MMCAP, administered by Minnesota's Office of State Procurement and serving multiple states including Oregon, issued an RFP (S1070000015802) due March 26, 2026 for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, with contract effectiveness July 1, 2026 and evaluation weighted heavily on price competitiveness (75 percent) alongside administrative compliance, EDI capability, and fixed pricing consistency.